A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
This application is a continuation-in-part of U.S. patent application Ser. No. 09/321,522, filed on May 27, 1999 now U.S. Pat. No. 6,303,607 which in turn claims priority to U.S. Provisional Patent Application Ser. No. 60/099,804 filed on Sep. 10, 1998.
